Abstract

Objectives: The aim was to investigate the effect of hepatitis C virus (HCV) infection treatment with direct-acting antiviral (DAA) drugs on patients' mood, sleep quality and quality of life (QoL). Methods: Chronic HCV-infected patients receiving DAAs were evaluated prospectively. Patients were evaluated before the beginning of treatment and 12-24 weeks after finishing their treatment duration using the Pittsburgh Sleep Quality Index, Beck depression inventory questionnaire and SF-36 healthrelated QoL questionnaires. Results: A total of 120 patients with a mean age of 41.03 +/- 7.68 years were evaluated (68.3 males). The mean follow-up duration was 141.79 +/- 27.88 days after finishing the treatment. Significant improvement in the scores of sleep quality (5.13 +/- 1.5 vs. 3.43 +/- 1.35), mood (12.77 +/- 4.02 vs. 9.27 +/- 3.14) and QoL (77.49 +/- 5.15 vs. 83.95 +/- 3.39) post treatment compared with pretreatment were observed (p < 0.05). Changes in patients' sleep and mood were not related to their QoL change (p > 0.05). Discussion: DAAs for the treatment of HCV have a significant effect on improving their sleep, mood and QoL. The changes in sleep quality, mood and QoL of patients were independent and were not affected by each other. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.